United States
Germany
FranceINFORMATION FOR MEDICAL PROFESSIONALS
Novel science is only part of the equation when it comes to developing new medicines. Clinical research depends upon partnerships with health care professionals and patient advocates and those who choose to participate in clinical trials.
Krystal is committed to supporting and partnering with the healthcare community across disease areas to provide information about research, treatments in development, access to investigational medicines and more.
Please contact us at [email protected] for more information about our clinical trials or visit our ClinicalTrials.gov listing at the link below.
For KB707, the U.S. FDA has granted Fast Track Designation:
· To delay disease progression in the treatment of patients with anti-PD-1 relapsed/refractory locally advanced or metastatic melanoma
· For the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy
Both treatments are accessible under the U.S. FDA Expanded Access Program program.
Please review our Expanded Access policy at the link below. For physicians seeking pre-approval access to one of our investigational drugs, please contact us at [email protected].
Discovering, developing, and commercializing genetic medicines with purpose
